Preview

Systemic Hypertension

Advanced search

Polypill" conception in modern cardiology

https://doi.org/10.26442/2075082X.2018.4.180116

Abstract

Combining treatments with antihypertensive, lipid lowering, antidiabetic and antiplatelet effects into a single pill significantly increases adherence to treatment, provides multiple control of risk factors and reduces the risk of cardiovascular diseases and fatal events. At the same time, there is still no convincing evidence that the using polypill in cardiology instead of the standard treatment strategy leads to a greater reduction in the incidence of primary end points (total mortality, fatal myocardial infarction, stroke, etc.)

About the Authors

I. E. Chazova
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


A. V. Aksenova
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


Yu. V. Zhernakova
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


References

1. Simpson S.H, Eurich D.T, Majumdar S.R et al. A meta-analysis of the ssociation between adherence to drug therapy and mortality. BMJ 2006; 333: 315.

2. Corrao G, Rea F, Ghirardi A et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66: 742-9.

3. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940-8.

4. Claxton A.J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.

5. Mancia G, Facchetti R, Bombelli M et al. Relationship of office, home,and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072-7.

6. Bhatt D.L, Steg P.G, Ohman E.M et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.

7. Hameed M.A, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354: i3268.

8. Ambrosioni E, Leonetti G, Pessina A.C et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691-9.

9. Gupta A.K, Arshad S, Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399-407.

10. Yusuf S, Pais P, Sigamani A et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463-71.

11. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Prac Cardiovasc Med 2009; 6: 101-10.

12. Thom S, Poulter N, Field J et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-29.

13. Selak V, Elley C.R, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348: g3318.

14. Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-30.

15. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). http://clinical trials.gov/ct2/show/NCT01271985

16. Castellano J.M, Bueno H, Fuster V. The cardiovascular polypill: clinical data and ongoing studies. Internat J Cardiol 2015; 201 (S1): S8-S14.

17. Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313: 603-15.

18. Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.


Review

For citations:


Chazova I.E., Aksenova A.V., Zhernakova Yu.V. Polypill" conception in modern cardiology. Systemic Hypertension. 2018;15(4):6-7. https://doi.org/10.26442/2075082X.2018.4.180116

Views: 307


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)